“The U.S. and Massachusetts in particular have been leaders in biologics innovation, creating new therapies for some of the most debilitating diseases impacting patients. Development of these new treatments and cures is dependent upon innovators being properly rewarded and their intellectual property being protected. The removal of enhanced IP protections for biologic medicines in the revised USMCA promises to jeopardize this ingenuity, opening the door for foreign free-riding on American medical innovation – something President Trump promised to end.”
– Robert K. Coughlin, President & CEO of MassBio